Mehdi Layeghifard

Senior RA @ SickKids -- GGB; Networks/ML/Genomics/CompBio; Childhood cancer.

[nature @Nature]

Nature research paper: Prior therapy defines mutation profiles in childhood cancer at relapse

https://t.co/I3rxRHW9Vq

[Waggoner Lab @LabWaggoner]

Mutagenic effects of chemotherapy on relapsed childhood tumours cataloguing each major drug’s associated mutational signatures & how this shapes disease at relapse or metastasis @Nature @mlayeghi @SickKidsNews 🇨🇦
https://t.co/gzcApYQE4t

[Mehdi Layeghifard @mlayeghi]

Our paper out today in @Nature:
How does prior therapy shape childhood cancer at the genomic level? 🧬

https://t.co/obm6ohm1nC
https://t.co/N1KHdpD5Y9

#Nature #CancerGenomics #MutationalSignatures #PrecisionMedicine #PediatricCancer #Resistance

[POGO @POGO4kids]

Ready to dive into the future of #PediatricOncology with a twist? Join us at the #POGOSymposium for Adam Shlien’s mind-blowing session on using Artificial Intelligence to improve the diagnostic accuracy of #ChildhoodCancers. Don’t miss out on this AI extravaganza! 🧠🚀

[Peter Munk Cardiac Centre AI @pmcc_ai]

Come join us on April 26 to hear Valli Subasri talk about her research at SickKids and UofT! Look forward to seeing you there @vallisubasri @SenthujanSenka @BoWang87 @PMunkCardiacCtr @UHN

[Cancer Research Communications @CRC_AACR]

Just published—
Multiple germline events contribute to cancer development in patients with #LiFraumenisyndrome, by @vallisubasri et al.
https://t.co/IZEpa4Spv0
@UofT @sickkids #openaccess

[Valli Subasri @vallisubasri]

✨Check out our study✨We use germline genetic and epigenetic data to identify diagnostic biomarkers, prognostic signatures, actionable therapeutic targets and correlates of clinical heterogeneity that will allow for improved clinical management of LFS patients!

[Mehdi Layeghifard @mlayeghi]

@vallisubasri Congratulations 🎊 👏

[The Hospital for Sick Children (SickKids) @SickKidsNews]

A new machine-learning platform could provide faster and more accurate diagnosis for children with cancer.
Developed by #SKResearch, the tool analyzed 13,000 individual cancers & can refine or match a diagnosis for 85% of #ChildhoodCancer patients.
Read➡️ https://t.co/l4Iamf5475

[Mehdi Layeghifard @mlayeghi]

Please check out this available position in our group at SickKids if you're interested in machine learning and computational oncology. #SickKids #ML #computational_oncology

https://t.co/GUU2dZbH4c

[Nathaniel D Anderson @natedandy_PhD]

Happy to share our preview on the spatial organization of microbiota in cancer published in @ImmunityCP.

Original paper by:
@CJohnstonLab1 @BullmanLab @fredhutch
https://t.co/HDSB0UKm9C

[Nick Light @nick_light]

Our study is out today in @NatureComms ! We analyzed cancer genomes from patients with Li-Fraumeni syndrome and found early copy number gain of the mutant allele of TP53 to be a characteristic feature of these tumours. https://t.co/QA3zXHTKGG

[Mehdi Layeghifard @mlayeghi]

Our new paper is out today on TP53 copy number gain in LFS syndrome! Congrats to @nick_light et al👏👏👏

#ShlienLab #MalkinLab #SickKids #LFS #TP53
@vallisubasri @natedandy_PhD

https://t.co/6gPDs9oetR

[Nature Cancer @NatureCancer]

💫ONLINE NOW @NatureCancer – „The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations” by #DavidMalkin #AdamShlien & Co.
👇
https://t.co/9kVIWAUCCr
https://t.co/9kVIWAUCCr

[Mehdi Layeghifard @mlayeghi]

An end-of-the-year publication from our KiCS Program. Enjoy reading!
https://t.co/NrOlKhuc6w

[The Hospital for Sick Children (SickKids) @SickKidsNews]

New #SKResearch led by Dr. Adam Shlien showcases RNAmp, a novel computational tool that directly measures hypertranscription in tumour cells, and highlights its potential to uncover previously unknown #cancer subtypes & new treatment pathways for patients. https://t.co/JPAWC4mPK7

[Sara Mostafavi @sara_mostafavi]

Machine Learning in Comp Bio (MLCB) 2022 schedule is available now: https://t.co/Fs1E54yFvA
Please register (it's free) to receive information about (virtually) watching the talks.

[Jüri Reimand @reimand]

Mutational processes & signatures in cancer genomes associate more with chromatin accessibility of cancers and less with normal tissues, perhaps as mut.processes are most active later in tumor evolution. Our study led by @oocsenas @PLOSCompBiol https://t.co/kNrflVdklg @OICR_news

[Mehdi Layeghifard @mlayeghi]

Another collab with Mohit Kapoor lab at #Krembil #TorontoWestern #UHN #miRNA #Spine #Osteoarthritis

https://t.co/daGtJbyYPB

[Mehdi Layeghifard @mlayeghi]

First foray into Metabolomics! Cool colab with #JasonRockel #MohitKapoor #UHN

Identification of a differential metabolite-based signature in patients with late-stage knee osteoarthritis.

https://t.co/wzkg1YZ9Pq